Novo Nordisk presents results from STRIDE study on Ozempic

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1, at the American College of Cardiology’s, ACC, Annual Scientific Session and Expo. The results were presented during a late-breaking clinical trial session and highlighted at an official ACC press conference. In addition, the analysis was also simultaneously published today in The Lancet. The double-blind, randomized, placebo-controlled STRIDE trial, which enrolled 792 adults with type 2 diabetes and symptomatic PAD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 13% superior improvement in maximum walking distance and a clinically meaningful median treatment difference of 26.4 meters on a 12% incline, compared to placebo at 52 weeks. The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed, including pain-free walking distance and Vascular Quality of Life Questionnaire-6 at 52 weeks. Serious adverse events were reported in 74 participants in the semaglutide arm and 78 participants in the placebo arm, and SAEs that were possibly/probably treatment-related occurred in 5 and 6 participants, respectively. SAEs led to the death of 3 and 8 participants in the semaglutide and placebo arms, respectively; however, no SAEs leading to death were treatment-related.